Jan Poth, SciRhom CEO
July 9, 2024 02:00 AM EDTUpdated 07:26 AM
Financing

Ger­man an­ti­body com­pa­ny se­cures €63M for au­toim­mune dis­ease pro­gram

Ayisha Sharma

News Reporter

SciRhom has raised €63 mil­lion ($70 mil­lion) in a Se­ries A to ad­vance its lead mon­o­clon­al an­ti­body pro­gram through a first-in-hu­man tri­al set to start …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Al­ny­lam’s new Phase 3 AT­TR da­ta bring un­cer­tain­ty to stan­dard of care am­bi­tions

Re­cur­sion nears ‘mo­ment of truth’ with first key da­ta, kick­ing off 18-month flur­ry of read­outs

Ipsen sells pri­or­i­ty re­view vouch­er for high­est price since 2016

J&J's hu­man re­sources leader to re­tire; Am­gen be­comes the newest phar­ma with a top AI ex­ec

Once one of im­muno-on­col­o­gy's next great hopes, CD47 faces fi­nal shots on goal

Mer­ck opens Lon­don lab as it makes push in­to im­munol­o­gy and the UK

A service from the Financial Times